Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
- PMID: 20016845
- PMCID: PMC2788595
- DOI: 10.2147/vhrm.s4502
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Abstract
Although statins reduce cardiovascular morbidity and mortality further risk reduction is needed. In this respect low HDL-cholesterol concentrations and/or elevated triglyceride concentrations may be potential treatment targets. Niacin (nicotinic acid) is an effective drug which increases the plasma concentration of high-density lipoprotein (HDL)-cholesterol and decreases the concentration of low-density lipoprotein (LDL)-cholesterol, triglycerides and lipoprotein(a). Clinical studies indicate that niacin can significantly reduce the risk for cardiovascular events. However, niacin is not very commonly used because of significant side effects (especially flushing). Laropiprant is a potent selective antagonist of PGD2-receptor subtype-1 and can thus reduce niacin-induced flushing. Although the addition of laropiprant will reduce the frequency of flushing, it will not completely eliminate this side effect. Laropiprant does not change the effect of niacin on lipids or other side effects of niacin (ie, gastro-intestinal problems, glucose elevation). The combination of niacin with laropiprant may therefore enable use of niacin at higher doses and therefore exploit the full potential of the drug. Endpoint studies that will be published over the next few years will show whether this treatment modality also translates into clinical effect in patients treated with statins. Until publication of these studies niacin/laropiprant should be used only in high-risk patients not achieving lipid goals on statins.
Keywords: dyslipoproteinemia; flushing; hyperlipidemia; nicotinic acid.
Figures

Similar articles
-
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.Cardiol Clin. 2008 Nov;26(4):547-60. doi: 10.1016/j.ccl.2008.06.007. Cardiol Clin. 2008. PMID: 19031552 Review.
-
Extended-release niacin (nicotinic acid)/laropiprant.Drugs. 2009 Aug 20;69(12):1665-79. doi: 10.2165/11203730-000000000-00000. Drugs. 2009. PMID: 19678716 Review.
-
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.Vasc Health Risk Manag. 2014 May 7;10:279-90. doi: 10.2147/VHRM.S58694. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 24855368 Free PMC article. Clinical Trial.
-
Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.Expert Opin Pharmacother. 2010 Jul;11(10):1715-26. doi: 10.1517/14656566.2010.489894. Expert Opin Pharmacother. 2010. PMID: 20518616 Review.
-
Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.Curr Vasc Pharmacol. 2011 Jul 1;9(4):385-400. doi: 10.2174/157016111796197279. Curr Vasc Pharmacol. 2011. PMID: 21314635 Review.
Cited by
-
The effect of niacin on serum phosphorus levels in dialysis patients.Indian J Nephrol. 2012 May;22(3):174-8. doi: 10.4103/0971-4065.98751. Indian J Nephrol. 2012. PMID: 23087550 Free PMC article.
-
Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.Clin Med Insights Cardiol. 2011;5:85-101. doi: 10.4137/CMC.S7601. Epub 2011 Sep 19. Clin Med Insights Cardiol. 2011. PMID: 22084607 Free PMC article.
-
High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.Curr Cardiol Rev. 2017;13(3):168-182. doi: 10.2174/1573403X13666170209145622. Curr Cardiol Rev. 2017. PMID: 28190386 Free PMC article. Review.
-
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.Br J Pharmacol. 2012 Nov;167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x. Br J Pharmacol. 2012. PMID: 22725625 Free PMC article. Review.
-
Attenuation of niacin-induced prostaglandin D(2) generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells.J Inflamm Res. 2012;5:37-50. doi: 10.2147/JIR.S29044. Epub 2012 Mar 14. J Inflamm Res. 2012. PMID: 22442634 Free PMC article.
References
-
- Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206. - PubMed
-
- Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352:1685–1695. - PubMed
-
- Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. - PubMed
-
- Cholesterol Treatment Trialists’ (CTT) Collaborators. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysis. Lancet. 2008;371:117–125. - PubMed
-
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical